^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Hematological Malignancies

    Related cancers:
    1d
    ACCESS: Addressing Cancer Care Equity With Social Determinants of Health Screening and Early Intervention (clinicaltrials.gov)
    P=N/A, N=80, Not yet recruiting, Massachusetts General Hospital
    New trial
    1d
    MARINA: A Non-interventional Study of Melphalan Flufenamide (Melflufen) (Pepaxti®) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma (R/RMM) (clinicaltrials.gov)
    P=N/A, N=50, Recruiting, iOMEDICO AG | Not yet recruiting --> Recruiting
    Enrollment open
    |
    dexamethasone • Melflufen (melphalan flufenamide)
    1d
    Carfil-HAD: Secure Outsourcing of Carfilzomib in the Treatment of Multiple Myeloma to the Hospital at Home Setting (clinicaltrials.gov)
    P=N/A, N=17, Completed, University Hospital, Limoges | Recruiting --> Completed
    Trial completion
    |
    carfilzomib
    1d
    VA Consolidation in Intermediate-Risk AML (clinicaltrials.gov)
    P2, N=226, Recruiting, The First Affiliated Hospital of Soochow University
    New P2 trial
    |
    Venclexta (venetoclax) • cytarabine • azacitidine
    1d
    RELATIVITY-069: A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=5, Terminated, Bristol-Myers Squibb | Completed --> Terminated
    Trial termination
    |
    Opdivo (nivolumab) • relatlimab (BMS-986016)
    1d
    Biodistribution, Dosimetry, and Safety of 68Ga-EV203 in Hematological Malignancies (clinicaltrials.gov)
    P=N/A, N=30, Recruiting, Zhejiang Cancer Hospital
    New trial
    1d
    GoFast CAR T-Cell Therapy for Recurrent Refractory B-Cell Lymphoma (clinicaltrials.gov)
    P1, N=9, Not yet recruiting, Chinese PLA General Hospital
    New P1 trial
    |
    CD19 positive
    |
    cyclophosphamide • fludarabine IV
    1d
    IBEX: Iberdomide and Daratumumab as Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma (clinicaltrials.gov)
    P2, N=60, Recruiting, Barbara Ann Karmanos Cancer Institute | Trial completion date: Dec 2026 --> Dec 2028 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    clonoSEQ®
    |
    Darzalex Faspro (daratumumab and hyaluronidase-fihj) • iberdomide (CC-220)
    1d
    DR-18 to Prevent or Treat Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse After Hematopoietic Cell Transplantation, the DR. DREAM Trial (clinicaltrials.gov)
    P1, N=40, Recruiting, Fred Hutchinson Cancer Center | N=20 --> 40
    Enrollment change
    |
    TP53 (Tumor protein P53) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    TP53 mutation
    |
    vevoctadekin (ST-067)
    1d
    AugMMent: GMMG-HD11/DSMM XXI/64007957MMY3010 (clinicaltrials.gov)
    P3, N=399, Not yet recruiting, University of Heidelberg Medical Center
    New P3 trial
    |
    lenalidomide • bortezomib • Darzalex (daratumumab) • melphalan • Tecvayli (teclistamab-cqyv)
    1d
    NADERIN-BC: Prophylaxis of Hematologic Complications With Naderin in First-Line Breast Cancer Chemotherapy (clinicaltrials.gov)
    P2/3, N=79, Completed, MIPO Clinic
    New P2/3 trial
    |
    doxorubicin hydrochloride • cyclophosphamide
    1d
    A Study of MRD-Guided Zanubrutinib Plus Sonrotoclax in Treatment-Naïve, High-Risk CLL/SLL Patients (clinicaltrials.gov)
    P2, N=24, Recruiting, The First Affiliated Hospital with Nanjing Medical University
    New P2 trial
    |
    TP53 (Tumor protein P53) • IGH (Immunoglobulin Heavy Locus)
    |
    TP53 mutation • Chr del(11q) • TP53 mutation + Chr del(17p)
    |
    Brukinsa (zanubrutinib) • Beqalzi (sonrotoclax)